Bio-Techne Corporation (TECH)
$
48.4
+0.07 (0.14%)
Key metrics
Financial statements
Free cash flow per share
1.4028
Market cap
7.5 Billion
Price to sales ratio
6.2161
Debt to equity
0.2099
Current ratio
3.7070
Income quality
2.0117
Average inventory
189.7 Million
ROE
0.0634
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Bio-Techne Corporation, along with its subsidiaries, specializes in the development, manufacture, and sale of life science reagents, instruments, and services targeting the research and clinical diagnostics sectors globally. The company operates through two primary segments: Protein Sciences and Diagnostics and Genomics. In the Protein Sciences segment, Bio-Techne develops and manufactures biological reagents utilized in various facets of life science research, diagnostics, and cell and gene therapies. This includes cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. Additionally, this segment provides proteomic analytical tools that facilitate automated western blotting and multiplexed ELISA workflows, comprising both manual and automated protein analysis instruments as well as immunoassays designed to quantify proteins across multiple biological fluids. In its Diagnostics and Genomics segment, Bio-Techne is engaged in the development and manufacture of diagnostic products including controls, calibrators, and diagnostic assays tailored for the regulated diagnostics market. This segment also focuses on exosome-based molecular diagnostics, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, along with genetic and oncology kits suitable for research and clinical applications. The company reported a net income of $168,105,000.00 reflecting its profitability, while also earning an interest income of $3,323,000.00 showcasing its financial investments. The earnings per share (EPS) is reported at $1.07 indicating the company's profitability on a per-share basis. However, it incurred an interest expense of $15,736,000.00 reflecting its debt servicing obligations. The total operating expenses amount to $563,039,000.00 encompassing various operational costs incurred throughout its business operations. Bio-Techne is characterized by a stock deemed reasonably priced at $48.33 which is appealing to a broad range of investors. The stock also enjoys an average trading volume of 2,354,952.00 indicating moderate liquidity in the market. With a mid-range market capitalization of $7,587,522,800.00 the company stands out as a steady performer in the life sciences field. It plays a pivotal role in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within the life sciences arena.
Is Bio-Techne Corporation (TECH) a good investment?
Investing in Bio-Techne Corporation (TECH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Bio-Techne Corporation (TECH)'s stock forecast?
Analysts predict Bio-Techne Corporation stock to fluctuate between $46.01 (low) and $83.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Bio-Techne Corporation's market capitalization?
As of 2025-05-30, Bio-Techne Corporation's market cap is $7,587,522,800, based on 156,767,000 outstanding shares.
How does Bio-Techne Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Bio-Techne Corporation has a Lower Market-Cap, indicating a difference in performance.
Does Bio-Techne Corporation pay dividends?
Bio-Techne Corporation pays dividends. The current dividend yield is 0.65%, with a payout of $0.08 per share.
How can I buy Bio-Techne Corporation (TECH) stock?
To buy Bio-Techne Corporation (TECH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TECH. Place an order (Market, Limit, etc.).
What is the best time to invest in Bio-Techne Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Bio-Techne Corporation stock ever split?
Bio-Techne Corporation's last stock split was 4:1 on 2022-11-30.
How did Bio-Techne Corporation perform in the last earnings report?
Revenue: $1,159,060,000 | EPS: $1.07 | Growth: -40.88%.
Where can I find Bio-Techne Corporation's investor relations reports?
Visit https://www.bio-techne.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Bio-Techne Corporation?
You can explore historical data from here
What is the all-time high and low for Bio-Techne Corporation stock?
All-time high: $362.53 (2022-11-11) | All-time low: $46.01 (2025-04-21).
What are the key trends affecting Bio-Techne Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.
globenewswire.com
Antwerp, May 28, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) (“Golden Ocean”) are pleased to announce that they have signed an agreement and plan of merger (the “Merger Agreement”) for a stock-for-stock merger, as contemplated by the term sheet previously announced on 22 April 2025. The transaction is structured as a merger, with Golden Ocean merging with and into CMB.TECH Bermuda Ltd.
globenewswire.com
Antwerp, May 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) announces that today the General Meeting of Shareholders has approved the annual accounts for the year ended 31 December 2024. All other resolutions proposed by CMB.TECH's Supervisory Board have also been approved.
globenewswire.com
CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the first quarter ended 31 March 2025. HIGHLIGHTS Financial highlights: Profit of USD 40.4 million in Q1 2025 CMB.TECH increases its contract backlog by USD 921 million (to USD 2.94 billion) Corporate highlights: CMB.TECH buys Hemen stake in Golden Ocean Term sheet signed for a stock-for-stock merger transaction between CMB.TECH and Golden Ocean Fleet highlights: Fortescue and CMB.TECH sign agreement for ammonia-powered Newcastlemax CMB.TECH and MOL sign landmark agreement for nine ammonia-powered vessels Delivery of 5 newbuilding vessels: Mineral Portugal, Mineral Osterreich, Mineral Suomi, Mineral Sverige and CTV Hydrocat 60 Previously announced sales generated a capital gain of USD 46.25 million: Suezmax Cap Lara (2007, 158,826 dwt), VLCC Alsace (2012 – 299,999 DWT) and Windcat 6 Sale of three VLCCs in Q1 2025, Iris (2012, 314,000 dwt), Hakata (2010, 302,550 dwt) & Hakone (2010, 302,624 dwt) as part of the fleet rejuvenation strategy.
globenewswire.com
Antwerp, May 12, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2025 earnings prior to market opening on Thursday 21 May 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.
benzinga.com
Capital Link's Trending News Webinar Series featured this week a discussion with Mr. Alexander Saverys, CEO of CMB.TECH CMBT, who shared his views on the company's diversified business model, plans for decarbonization, and his vision for a maritime industry that balances tradition with bold innovation.
prnewswire.com
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
prnewswire.com
MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
seekingalpha.com
Bio-Techne Corporation (NASDAQ:TECH ) Q3 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President & Chief Executive Officer Jim Hippel - Executive Vice President & Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Daniel Markowitz - Evercore Dan Arias - Stifel Thomas DeBourcy - Nephron Research Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode, and the call will be open for questions following the management's prepared remarks.
zacks.com
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
See all news
